Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2013

Open Access 01-12-2013 | Research article

Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension

Authors: James Twiss, Stephen McKenna, Louise Ganderton, Sue Jenkins, Mitra Ben-L’amri, Kevin Gain, Robin Fowler, Eli Gabbay

Published in: BMC Pulmonary Medicine | Issue 1/2013

Login to get access

Abstract

Background

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and the Medical Outcomes Study Short Form 36 (SF-36) are widely used to assess patient-reported outcome in individuals with pulmonary hypertension (PH). The aim of the study was to compare the psychometric properties of the two measures.

Methods

Participants were recruited from specialist PH centres in Australia and New Zealand. Participants completed the CAMPHOR and SF-36 at two time points two weeks apart. The SF-36 is a generic health status questionnaire consisting of 36 items split into 8 sections. The CAMPHOR is a PH-specific measure consisting of 3 scales; symptoms, activity limitations and needs-based QoL. The questionnaires were assessed for distributional properties (floor and ceiling effects), internal consistency (Cronbach's alpha), test-retest reliability and construct validity (scores by World Health Organisation functional classification).

Results

The sample comprised 65 participants (mean (SD) age = 57.2 (14.5) years; n(%) male = 14 (21.5%)). Most of the patients were in WHO class 2 (27.7%) and 3 (61.5%). High ceiling effects were observed for the SF-36 bodily pain, social functioning and role emotional domains. Test-retest reliability was poor for six of the eight SF-36 domains, indicating high levels of random measurement error. Three of the SF-36 domains did not distinguish between WHO classes. In contrast, all CAMPHOR scales exhibited good distributional properties, test retest reliability and distinguished between WHO functional classes.

Conclusions

The CAMPHOR exhibited superior psychometric properties, compared with the SF-36, in the assessment of PH patient-reported outcome.
Literature
1.
go back to reference Rubin LJ: Primary pulmonary hypertension. N Engl J Med. 1997, 336 (2): 111-117. 10.1056/NEJM199701093360207.CrossRefPubMed Rubin LJ: Primary pulmonary hypertension. N Engl J Med. 1997, 336 (2): 111-117. 10.1056/NEJM199701093360207.CrossRefPubMed
2.
go back to reference Rudarakanchana N, Trembath RC, Morrell NW: New insights into the pathogenesis and treatment of primary pulmonary hypertension. Thorax. 2001, 56 (11): 888-890. 10.1136/thorax.56.11.888.CrossRefPubMedPubMedCentral Rudarakanchana N, Trembath RC, Morrell NW: New insights into the pathogenesis and treatment of primary pulmonary hypertension. Thorax. 2001, 56 (11): 888-890. 10.1136/thorax.56.11.888.CrossRefPubMedPubMedCentral
3.
go back to reference Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S: An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007, 30: 104-109. 10.1183/09031936.00092306.CrossRefPubMed Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S: An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007, 30: 104-109. 10.1183/09031936.00092306.CrossRefPubMed
4.
go back to reference Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, Gabbay E, et al: Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012, 98 (24): 1805-11. 10.1136/heartjnl-2012-301992.CrossRefPubMedPubMedCentral Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, Gabbay E, et al: Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012, 98 (24): 1805-11. 10.1136/heartjnl-2012-301992.CrossRefPubMedPubMedCentral
5.
go back to reference Rubin LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004, 126 (1 Suppl): 7S-10S.CrossRefPubMed Rubin LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004, 126 (1 Suppl): 7S-10S.CrossRefPubMed
6.
go back to reference Wryobeck J, Lippo G, McLaughlin V, Riba M, Rubenfire M: Psychosocial aspects of pulmonary hypertension: a review. Psychosomatics. 2007, 48: 467-475. 10.1176/appi.psy.48.6.467.CrossRefPubMed Wryobeck J, Lippo G, McLaughlin V, Riba M, Rubenfire M: Psychosocial aspects of pulmonary hypertension: a review. Psychosomatics. 2007, 48: 467-475. 10.1176/appi.psy.48.6.467.CrossRefPubMed
7.
go back to reference Rubenfire M, Lippo G, Bodinia B, Blasi F, Allegra L, Bossone E: Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension. Chest. 2009, 136: 597-603. 10.1378/chest.08-1260.CrossRefPubMed Rubenfire M, Lippo G, Bodinia B, Blasi F, Allegra L, Bossone E: Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension. Chest. 2009, 136: 597-603. 10.1378/chest.08-1260.CrossRefPubMed
8.
go back to reference Lowe B, Grafe K, Ufer C, et al: Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004, 66: 831-836. 10.1097/01.psy.0000145593.37594.39.CrossRefPubMed Lowe B, Grafe K, Ufer C, et al: Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004, 66: 831-836. 10.1097/01.psy.0000145593.37594.39.CrossRefPubMed
9.
go back to reference McCollister DH, Beutz M, McLaughlin V: Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010, 51 (4): 339-339. e8CrossRefPubMed McCollister DH, Beutz M, McLaughlin V: Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010, 51 (4): 339-339. e8CrossRefPubMed
10.
go back to reference Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 1999, 156 (6): 837-841.CrossRefPubMed Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 1999, 156 (6): 837-841.CrossRefPubMed
11.
go back to reference Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M: Measurement of quality of life in pulmonary hypertension and its significance. Eur Resp J. 2006, 28: 808-815. 10.1183/09031936.06.00130405.CrossRef Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M: Measurement of quality of life in pulmonary hypertension and its significance. Eur Resp J. 2006, 28: 808-815. 10.1183/09031936.06.00130405.CrossRef
12.
go back to reference Chua R, Keogh AM, Byth K, O'Loughlin A: Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006, 36 (11): 705-10. 10.1111/j.1445-5994.2006.01169.x.CrossRefPubMed Chua R, Keogh AM, Byth K, O'Loughlin A: Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006, 36 (11): 705-10. 10.1111/j.1445-5994.2006.01169.x.CrossRefPubMed
13.
go back to reference McKenna SP: Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011, 14 (9): 86-CrossRef McKenna SP: Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011, 14 (9): 86-CrossRef
14.
go back to reference Ware JE, Kosinski M, Dewey JE: How to score version two of the SF-36 health survey. 2000, QualityMetric, Incorporated: Lincoln, RI Ware JE, Kosinski M, Dewey JE: How to score version two of the SF-36 health survey. 2000, QualityMetric, Incorporated: Lincoln, RI
15.
go back to reference McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006, 15 (1): 103-15. 10.1007/s11136-005-3513-4.CrossRefPubMed McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006, 15 (1): 103-15. 10.1007/s11136-005-3513-4.CrossRefPubMed
16.
go back to reference Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, Bogossian H: Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin. 2005, 21 (6): 907-11. 10.1185/030079905X46232.CrossRefPubMed Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, Bogossian H: Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin. 2005, 21 (6): 907-11. 10.1185/030079905X46232.CrossRefPubMed
17.
go back to reference Pepke-Zaba J, Gilbert C, Collings L, Brown MC: Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2008, 133 (1): 183-9. 10.1378/chest.07-0592.CrossRefPubMed Pepke-Zaba J, Gilbert C, Collings L, Brown MC: Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2008, 133 (1): 183-9. 10.1378/chest.07-0592.CrossRefPubMed
18.
go back to reference Mok MY, Tsang PL, Lam YM, Lo Y, Wong WS, Lau CS: Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus. 2007, 16 (4): 279-85. 10.1177/0961203307076509.CrossRefPubMed Mok MY, Tsang PL, Lam YM, Lo Y, Wong WS, Lau CS: Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus. 2007, 16 (4): 279-85. 10.1177/0961203307076509.CrossRefPubMed
19.
go back to reference Wong RC, Koh GM, Choong PH, Yip WL: Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Int J Cardiol. 2007, 119 (3): 400-2. 10.1016/j.ijcard.2006.07.170.CrossRefPubMed Wong RC, Koh GM, Choong PH, Yip WL: Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Int J Cardiol. 2007, 119 (3): 400-2. 10.1016/j.ijcard.2006.07.170.CrossRefPubMed
20.
go back to reference Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2009, 135 (1): 137-42. 10.1378/chest.07-0275.CrossRefPubMed Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2009, 135 (1): 137-42. 10.1378/chest.07-0275.CrossRefPubMed
21.
go back to reference McKenna SP, Ratcliffe J, Meads DM, Brazier JE: Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008, 6: 65-10.1186/1477-7525-6-65.CrossRefPubMedPubMedCentral McKenna SP, Ratcliffe J, Meads DM, Brazier JE: Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008, 6: 65-10.1186/1477-7525-6-65.CrossRefPubMedPubMedCentral
22.
go back to reference Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J: The responsiveness and validity of the CAMPHOR utility index. Respir J. 2008, 32 (6): 1513-1519. 10.1183/09031936.00069708.CrossRef Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J: The responsiveness and validity of the CAMPHOR utility index. Respir J. 2008, 32 (6): 1513-1519. 10.1183/09031936.00069708.CrossRef
23.
go back to reference Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E: Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) in Australian and New Zealand populations. Respirology. 2011, 16: 1235-1240. 10.1111/j.1440-1843.2011.02030.x.CrossRefPubMed Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E: Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) in Australian and New Zealand populations. Respirology. 2011, 16: 1235-1240. 10.1111/j.1440-1843.2011.02030.x.CrossRefPubMed
24.
go back to reference Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A: Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004, 43: 5S-12S. 10.1016/j.jacc.2004.02.037.CrossRefPubMed Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A: Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004, 43: 5S-12S. 10.1016/j.jacc.2004.02.037.CrossRefPubMed
25.
go back to reference Streiner D, Norman G: Health measurement scales. 1989, Oxford: Oxford University Press Streiner D, Norman G: Health measurement scales. 1989, Oxford: Oxford University Press
26.
go back to reference Weiner EA, Stewart BJ: Assessing individuals. 1984, Boston: Little Brown Weiner EA, Stewart BJ: Assessing individuals. 1984, Boston: Little Brown
27.
go back to reference Matura LA, McDonough A, Carroll DL: Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012, 11 (1): 51-61. 10.1177/1474515111429649.CrossRefPubMed Matura LA, McDonough A, Carroll DL: Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012, 11 (1): 51-61. 10.1177/1474515111429649.CrossRefPubMed
28.
go back to reference Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD: Comparison of cardiac and pulmonary specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011, 38: 608-616. 10.1183/09031936.00161410.CrossRefPubMedPubMedCentral Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD: Comparison of cardiac and pulmonary specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011, 38: 608-616. 10.1183/09031936.00161410.CrossRefPubMedPubMedCentral
29.
go back to reference Simon GE, Revicki DA, Grothaus L, Vonkor M: SF-36 summary scores. Are physical and mental health truly distinct?. Med Care. 1998, 36: 567-72. 10.1097/00005650-199804000-00012.CrossRefPubMed Simon GE, Revicki DA, Grothaus L, Vonkor M: SF-36 summary scores. Are physical and mental health truly distinct?. Med Care. 1998, 36: 567-72. 10.1097/00005650-199804000-00012.CrossRefPubMed
30.
go back to reference Taft C, Karlsson J, Sullivan M: Do SF-36 summary scores accurately summarise subscale scores?. Qual Life Res. 2001, 10: 395-404. 10.1023/A:1012552211996.CrossRefPubMed Taft C, Karlsson J, Sullivan M: Do SF-36 summary scores accurately summarise subscale scores?. Qual Life Res. 2001, 10: 395-404. 10.1023/A:1012552211996.CrossRefPubMed
31.
go back to reference Wilson D, Parsons J, Tucker G: The SF-36 summary scales: problems and solutions. Soz Praventivmed. 2000, 45: 239-246. 10.1007/BF01591686.CrossRefPubMed Wilson D, Parsons J, Tucker G: The SF-36 summary scales: problems and solutions. Soz Praventivmed. 2000, 45: 239-246. 10.1007/BF01591686.CrossRefPubMed
32.
go back to reference Farrivar SS, Cunningham WE, Hays RD: Correlated physical and mental health summary scores for the SF-36 and SF-12 health survey. Health Qual Life Outcomes. 2007, 5: 54-10.1186/1477-7525-5-54.CrossRef Farrivar SS, Cunningham WE, Hays RD: Correlated physical and mental health summary scores for the SF-36 and SF-12 health survey. Health Qual Life Outcomes. 2007, 5: 54-10.1186/1477-7525-5-54.CrossRef
33.
go back to reference Hann M, Reeves D: The SF-36 summary scales are not accurately summarized by independent physical and mental component scores. Qual Life Res. 2008, 17: 413-23. 10.1007/s11136-008-9310-0.CrossRefPubMed Hann M, Reeves D: The SF-36 summary scales are not accurately summarized by independent physical and mental component scores. Qual Life Res. 2008, 17: 413-23. 10.1007/s11136-008-9310-0.CrossRefPubMed
34.
go back to reference Agnastopoulos F, Niakis D, Tountas Y: Comparison between exploratory factor analytic and SEM-based approaches to constructing SF-36 summary scores. Qual Life Res. 2009, 18: 53-63. 10.1007/s11136-008-9423-5.CrossRef Agnastopoulos F, Niakis D, Tountas Y: Comparison between exploratory factor analytic and SEM-based approaches to constructing SF-36 summary scores. Qual Life Res. 2009, 18: 53-63. 10.1007/s11136-008-9423-5.CrossRef
35.
go back to reference Fleishman JA, Selim AJ, Kasiz LE: Deriving SF-12 v2 physical and mental health summary scores: a comparison of different scoring algorithms. Qual Life Res. 2010, 19 (2): 231-41. 10.1007/s11136-009-9582-z.CrossRefPubMed Fleishman JA, Selim AJ, Kasiz LE: Deriving SF-12 v2 physical and mental health summary scores: a comparison of different scoring algorithms. Qual Life Res. 2010, 19 (2): 231-41. 10.1007/s11136-009-9582-z.CrossRefPubMed
36.
go back to reference Tucker G, Adams R, Wilson D: Observed agreement problems between Sub-scales and summary components of the SF-36 version 2 - an alternative scoring method can correct the problem. PLoS One. 2013, 12: 8(4)- Tucker G, Adams R, Wilson D: Observed agreement problems between Sub-scales and summary components of the SF-36 version 2 - an alternative scoring method can correct the problem. PLoS One. 2013, 12: 8(4)-
37.
go back to reference Strange G, Keogh AM, Williams TJ, Wlodarczyk J, Mcneil KD, Gabbay E: Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology. 2008, 13: 674-682. 10.1111/j.1440-1843.2008.01326.x.CrossRefPubMed Strange G, Keogh AM, Williams TJ, Wlodarczyk J, Mcneil KD, Gabbay E: Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology. 2008, 13: 674-682. 10.1111/j.1440-1843.2008.01326.x.CrossRefPubMed
38.
go back to reference Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N, Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group: Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011, 183 (12): 1723-1729. 10.1164/rccm.201101-0093OC.CrossRefPubMed Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N, Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group: Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011, 183 (12): 1723-1729. 10.1164/rccm.201101-0093OC.CrossRefPubMed
Metadata
Title
Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension
Authors
James Twiss
Stephen McKenna
Louise Ganderton
Sue Jenkins
Mitra Ben-L’amri
Kevin Gain
Robin Fowler
Eli Gabbay
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2013
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-13-45

Other articles of this Issue 1/2013

BMC Pulmonary Medicine 1/2013 Go to the issue